Dr. Alvarnas on Stem Cell Transplant for HIV-Associated Lymphoma

Joseph Alvarnas, MD
Published: Thursday, Jan 15, 2015



Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.

A​ recent phase II study compared HIV-associated lymphoma with lymphoma patients without HIV and found that both groups had similar outcomes after AHCT. The one-year survival rate for the HIV-lymphoma patients was 86%.

This research is extremely promising, says Alvarnas, because it was previously believed that those with HIV-associated lymphoma could not undergo transplant safely and were instead treated with minimal chemotherapy or less intense therapies.



Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.

A​ recent phase II study compared HIV-associated lymphoma with lymphoma patients without HIV and found that both groups had similar outcomes after AHCT. The one-year survival rate for the HIV-lymphoma patients was 86%.

This research is extremely promising, says Alvarnas, because it was previously believed that those with HIV-associated lymphoma could not undergo transplant safely and were instead treated with minimal chemotherapy or less intense therapies.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x